Physician profile
Maher Dakroub
NPI 1427438928
$20,808.97
in general payments reported to CMS, 2019-2025
73 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $1,625 · 2021: $1,154 · 2022: $4,995 · 2023: $5,465 · 2024: $5,322 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $537 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,816.66 |
| Education | $536.62 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,932.28 | 2020-2025 | |
| Incyte Corporation | $1,442.73 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $1,140.46 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $1,094.22 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,034.38 | 2021-2025 | Darzalex, Rybrevant, Talvey |
| E.R. Squibb & Sons, L.L.C. | $939.38 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $871.05 | 2019-2025 | |
| Eisai INC. | $779.47 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $722.30 | 2019-2024 | Enhertu, Tagrisso, Imfinzi |
| Daiichi Sankyo INC. | $703.37 | 2021-2025 | Enhertu |
| Seagen INC. | $689.35 | 2019-2023 | Adcetris, Padcev, Tivdak |
| Genzyme Corporation | $606.45 | 2019-2024 | |
| Astellas Pharma US INC | $588.27 | 2020-2024 | Xospata, Padcev, Xtandi |
| Glaxosmithkline, LLC. | $576.46 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $457.05 | 2019-2024 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.34 | 2020-2025 | Venclexta, Lupron Depot |
| Lilly USA, LLC | $447.39 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $439.47 | 2019-2024 | Venclexta, Polivy, Lunsumio |
| Gilead Sciences, INC. | $436.68 | 2022-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $422.81 | 2022-2024 | Ninlaro, Alunbrig, Iclusig |
| Amgen INC. | $374.86 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Karyopharm Therapeutics INC. | $302.84 | 2021-2025 | Xpovio |
| Blueprint Medicines Corporation | $282.04 | 2022-2025 | Ayvakit |
| Exelixis INC. | $250.21 | 2019-2024 | Cabometyx |
| Pharmaessentia USA Corporation | $188.30 | 2022-2025 | Besremi |
| Myovant Sciences INC. | $187.35 | 2022 | |
| Emd Serono, INC. | $183.54 | 2024 | |
| Alexion Pharmaceuticals, INC. | $181.74 | 2022-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $180.07 | 2022-2023 | Imbruvica |
| Dova Pharmaceuticals | $179.44 | 2019-2020 | |
| Puma Biotechnology, INC. | $166.63 | 2022-2025 | Nerlynx |
| Sobi, INC | $164.39 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $144.29 | 2021-2024 | Tazverik, Somatuline Depot, Onivyde |
| Rigel Pharmaceuticals, INC. | $142.95 | 2019-2023 | Tavalisse, Rezlidhia |
| Sumitomo Pharma America, INC. | $138.59 | 2023 | Orgovyx |
| Stemline Therapeutics INC. | $137.06 | 2023-2024 | Orserdu, Elzonris |
| Taiho Oncology, INC. | $131.73 | 2022-2025 | |
| Genmab U.S., INC. | $120.26 | 2023-2025 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.74 | 2022-2024 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $88.16 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $85.80 | 2020-2024 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $85.01 | 2021-2024 | Qinlock |
| Eusa Pharma (US) LLC | $80.06 | 2022 | |
| Tersera Therapeutics LLC | $71.40 | 2022-2023 | Zoladex |
| Tolmar Pharmaceuticals, INC. | $69.94 | 2022 | |
| Novocure INC. | $57.63 | 2021-2025 | Optune Lua (Novottf-200t) |
| Adc Therapeutics America, INC. | $57.31 | 2024 | |
| Aveo Pharmaceuticals, INC. | $56.91 | 2022-2024 | |
| Intuitive Surgical, INC. | $56.38 | 2024 | |
| Beigene USA, INC. | $55.93 | 2022-2023 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $55.74 | 2023-2025 | Pylarify |
| Epizyme, INC. | $49.42 | 2021-2022 | |
| Chiesi USA, INC. | $49.05 | 2023-2024 | Ferriprox |
| Immunogen, INC. | $47.47 | 2023-2024 | Elahere, Elahere |
| Springworks Therapeutics, INC. | $47.28 | 2024 | Ogsiveo |
| Regeneron Healthcare Solutions, INC. | $37.95 | 2024 | Libtayo |
| Mirati Therapeutics, INC. | $34.15 | 2023-2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $32.27 | 2022 | |
| Acrotech Biopharma INC. | $32.10 | 2023 | Beleodaq |
| Kite Pharma, INC. | $30.38 | 2022 | |
| Array Biopharma INC | $28.89 | 2024 | Tukysa, Braftovi, Mektovi |
| Coherus Oncology, INC. | $25.55 | 2024 | |
| Morphosys, US INC. | $24.89 | 2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $24.60 | 2022 | |
| Recordati_rare_diseases_inc. | $24.05 | 2023 | Sylvant |
| Sanofi-Aventis U.S. LLC | $23.90 | 2020 | |
| Macrogenics, INC. | $22.24 | 2022 | |
| Global Blood Therapeutics, INC. | $21.74 | 2022 | |
| Kyowa Kirin, INC. | $20.33 | 2019 | |
| Octapharma USA, INC. | $19.47 | 2020 | |
| Pharmacosmos Therapeutics INC. | $19.41 | 2023 | Monoferric |
| Clovis Oncology, INC. | $18.38 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Dakroub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.